| Detected | Trial | Change |
|---|---|---|
| 2026-06-02 | NCT07459751 A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43… |
overall status: "Enrolling By Invitation" → "Recruiting" |
| 2026-05-30 | NCT06115642 A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in… |
overall status: "Recruiting" → "Enrolling By Invitation" |
| 2026-05-30 | NCT07459751 A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43… |
overall status: "Not Yet Recruiting" → "Enrolling By Invitation" |
| 2026-05-29 | NCT07541534 A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors |
Recruitment opened |
| 2026-05-23 | NCT07477587 A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of… |
Recruitment opened |
| 2026-05-23 | NCT07477587 A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of… |
Trial sites expanded: 9 -> 81 locations |
| 2026-05-19 | NCT06769113 A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC… |
Enrollment increased: 72 -> 102 participants |
| 2026-05-19 | NCT06769113 A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC… |
Trial arms changed: 3 -> 4 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-22 | NCT07601620 A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo®… | Phase 1 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for… | Gastroesophageal-junction Cancer | Recruiting |
| NCT05353257 | A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With… | Limited-Stage Small Cell Lung Cancer | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT07294508 | A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive… | HER2 + Breast Cancer | Recruiting |
| NCT07459751 | A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43… | Advanced or Metastatic Squamous Non-Small Cell Lung Cancer | Recruiting |
| NCT07318883 | A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and… | Squamous NSCLC | Not Yet Recruiting |
| Phase 2 | |||
| NCT06857279 | A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head… | Carcinoma of Head and/or Neck | Recruiting |
| NCT06769152 | A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC)… | Cervical Cancer | Recruiting |
| NCT06769113 | A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC… | Esophageal Cancer | Recruiting |
| NCT07269782 | A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as… | Non Small Cell Lung Cancer | Recruiting |
| NCT07459738 | A Phase II Study to Evaluate the Efficacy and Safety of HLX43 in Patients With Hormone… | Hormone Receptor Positive HER-2 Negative Breast Cancer | Not Yet Recruiting |
| NCT07487519 | Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in… | Breast Cancer (Triple Negative Breast Cancer (TNBC)) | Not Yet Recruiting |
| NCT06812260 | A Single-arm, Open-label, Phase II Study to Evaluate Efficacy, Safety and… | SCLC, Extensive Stage | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT07358585 | A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With… | Colon Cancer Adenocarcinoma | Not Yet Recruiting |
| Phase 1 | |||
| NCT07176650 | Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and… | Hepatocellular Carcinoma (HCC) | Recruiting |
| NCT07416695 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of… | SCLC | Recruiting |
| NCT07160335 | A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity… | Non-small Cell Lung Cancer | Recruiting |
| NCT07477587 | A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of… | Multiple Myeloma (MM) | Recruiting |
| NCT07541534 | A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors | Advanced/Metastatic Solid Tumors | Recruiting |
| NCT07473726 | A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in… | Advanced/Metastatic Solid Tumors | Not Yet Recruiting |
| NCT07480681 | Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and… | Advanced/Metastatic Solid Tumors | Not Yet Recruiting |
| NCT07484893 | A Study to Evaluate the Safety, PK, and Immunogenicity of Recombinant Human Hyaluronidase… | Healthy Adult Male | Not Yet Recruiting |
| NCT07495930 | Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX319 Compared With… | Health Adult Subjects | Not Yet Recruiting |
| NCT07518043 | A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors | Esophageal and/or Cardia Cancer | Not Yet Recruiting |
| NCT07533708 | A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours | mCRPC or Advanced/Metastatic Solid Tumors | Not Yet Recruiting |
| NCT07543471 | A Phase I Multicentre Randomized Double-Blind Parallel-Controlled Study of HLX05-N vs… | mCRC | Not Yet Recruiting |